Gregory J. Riely

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Impact of DLL3 expression and tumor subtype on response to tarlatamab.

  Journal of Clinical Oncology · 2026-05-28

• Cancer type-specific variation in patterns of driver alterations across 50,000 tumors

  Cancer Cell · 2026-04-18

• Non–Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology

  Journal of the National Comprehensive Cancer Network · 2026-04-01 · 5 citations

• A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer

  Future Oncology · 2026-03-28

• Cancer type-specific variation in patterns of driver alterations across 50,000 tumors

  Cancer Cell · 2026-03-26 · 2 citations

• Outcomes and Toxicities of Definitive Radiation Therapy for Unresected Thymic Malignancies

  JTO Clinical and Research Reports · 2026-02-11

• Supplementary Table 2 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer

  2025-12-10

• Supplementary Figure 4 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer

  2025-12-10

• Supplementary Figure 6 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer

  2025-12-10

• Supplementary Table 3 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer

  2025-12-10

• Supplementary Figure 5 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer

  2025-12-10

• Supplementary Table 1 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer

  2025-12-10

• Supplementary Figure 1 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer

  2025-12-10

• Supplementary Figure 3 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer

  2025-12-10

• Supplementary Figure 2 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer

  2025-12-10

• Supplementary Figure S10 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer

  2025-11-25

• Supplementary Figure S1 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer

  2025-11-25

• Supplementary Figure S2 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer

  2025-11-25

• Supplementary Figure S12 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer

  2025-11-25

• Supplementary Data 1 from Early Changes in Circulating Cell-Free <i>KRAS</i> G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients

  2025-11-25